Cidara Therapeutics, Inc. (CDTX)
NASDAQ: CDTX · Real-Time Price · USD
21.70
+0.45 (2.12%)
At close: Jan 17, 2025, 4:00 PM
20.60
-1.10 (-5.07%)
Pre-market: Jan 21, 2025, 4:06 AM EST
Cidara Therapeutics Employees
Cidara Therapeutics had 69 employees as of December 31, 2023. The number of employees decreased by 4 or -5.48% compared to the previous year.
Employees
69
Change (1Y)
-4
Growth (1Y)
-5.48%
Revenue / Employee
$647,145
Profits / Employee
-$1,749,754
Market Cap
237.37M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
CDTX News
- 2 months ago - Cidara: Potential To Change Flu Prophylaxis Landscape With CD388 - Seeking Alpha
- 2 months ago - Cidara Therapeutics Announces $105 Million Private Placement - GlobeNewsWire
- 2 months ago - Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference - GlobeNewsWire
- 2 months ago - Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences - GlobeNewsWire
- 3 months ago - Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 4 months ago - Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference - GlobeNewsWire
- 4 months ago - Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza - GlobeNewsWire